{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T19:21:48Z","timestamp":1778527308832,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To assess the impact of early sotrovimab treatment versus no treatment on the risk of developing post-acute sequelae of COVID-19 (PASC; long COVID) in patients (age\u2009\u2265\u200912\u00a0years) with COVID-19 at high risk for progression to severe disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Retrospective cohort study using the US National COVID Cohort Collaborative (N3C) data. Phase 1 identified and assessed multiple definitions of PASC; Phase 2 evaluated the effectiveness of sotrovimab for reducing the risk of PASC, utilizing definitions from Phase 1. Average treatment effect in the treated (ATT)-weighted Cox proportional hazards regression models were used to compare time to event for PASC between high-risk patients who received sotrovimab treatment between May 26, 2021 and April 5, 2022, and high-risk patients with COVID-19 diagnosed between May 26, 2021 and March 26, 2022 who did not receive any treatment for COVID-19 during the acute phase or any pre-exposure prophylaxis against SARS-CoV-2.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 9,504 sotrovimab-treated and 619,668 untreated patients were included in the main analysis. Most baseline characteristics were balanced between the two cohorts after ATT weighting. The doubly robust ATT-weighted hazard ratio (95% confidence interval) was 0.92 (0.89\u20130.96) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), indicating that sotrovimab use was associated with a significantly lower risk of PASC. Results remained consistent in sensitivity analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In patients at high risk for severe COVID-19, the benefits of early sotrovimab treatment may extend beyond the acute phase of COVID-19 and contribute to the prevention of PASC symptoms.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s15010-025-02505-z","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T03:52:01Z","timestamp":1742701921000},"page":"1833-1849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of treatment of COVID-19 with sotrovimab on post-acute sequelae of COVID-19 (PASC): an analysis of National COVID Cohort Collaborative (N3C) data"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8994-2816","authenticated-orcid":false,"given":"Myriam","family":"Drysdale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4744-8067","authenticated-orcid":false,"given":"Jennifer","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4924-4810","authenticated-orcid":false,"given":"Helen","family":"Birch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Van Dyke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maral","family":"DerSarkissian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2265-9506","authenticated-orcid":false,"given":"Iain A.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"2505_CR1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.15585\/mmwr.mm7121e1","volume":"71","author":"L Bull-Otterson","year":"2022","unstructured":"Bull-Otterson L, Baca S, Saydah S, Boehmer TK, Adjei S, Gray S, et al. Post\u2013COVID conditions among adult COVID-19 survivors aged 18\u201364 and \u226565 years \u2014 United States, March 2020\u2013November 2021. MMWR Morb Mortal Wkly Rep. 2022;71:713\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"2505_CR2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2213-2600(23)00239-4","volume":"11","author":"M Parotto","year":"2023","unstructured":"Parotto M, Gyongyosi M, Howe K, Myatra SN, Ranzani O, Shankar-Hari M, et al. Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. Lancet Respir Med. 2023;11(8):739\u201354. https:\/\/doi.org\/10.1016\/S2213-2600(23)00239-4.","journal-title":"Lancet Respir Med"},{"key":"2505_CR3","unstructured":"National Center for Health Statistics. Long COVID. Household pulse survey. https:\/\/www.cdc.gov\/nchs\/covid19\/pulse\/long-covid.htm. Accessed March 19, 2024."},{"key":"2505_CR4","unstructured":"KFF. As recommendations for isolation end, how common is long COVID? https:\/\/www.kff.org\/coronavirus-covid-19\/issue-brief\/as-recommendations-for-isolation-end-how-common-is-long-covid\/. Accessed June 10, 2024."},{"issue":"1","key":"2505_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1101\/2023.12.21.23300305","volume":"22","author":"L-Y Lin","year":"2024","unstructured":"Lin L-Y, Henderson AD, Carlile O, Dillingham I, Butler-Cole BF, Marks M, et al. Healthcare utilisation in people with long COVID: an OpenSAFELY cohort study. BMC Med. 2024;22(1):255. https:\/\/doi.org\/10.1101\/2023.12.21.23300305.","journal-title":"BMC Med"},{"issue":"1","key":"2505_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12985-023-02061-8","volume":"20","author":"C Wang","year":"2023","unstructured":"Wang C, Ramasamy A, Verduzco-Gutierrez M, Brode WM, Melamed E. Acute and post-acute sequelae of SARS-CoV-2 infection: a review of risk factors and social determinants. Virol J. 2023;20(1):124. https:\/\/doi.org\/10.1186\/s12985-023-02061-8.","journal-title":"Virol J"},{"issue":"7","key":"2505_CR7","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/s41591-022-01840-0","volume":"28","author":"Z Al-Aly","year":"2022","unstructured":"Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461\u20137. https:\/\/doi.org\/10.1038\/s41591-022-01840-0.","journal-title":"Nat Med"},{"key":"2505_CR8","doi-asserted-by":"publisher","first-page":"101019","DOI":"10.1016\/j.eclinm.2021.101019","volume":"38","author":"HE Davis","year":"2021","unstructured":"Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re\u2019em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38: 101019. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101019.","journal-title":"EClinicalMedicine"},{"key":"2505_CR9","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.12688\/f1000research.27287.2","volume":"9","author":"I Doykov","year":"2020","unstructured":"Doykov I, Hallqvist J, Gilmour KC, Grandjean L, Mills K, Heywood WE. \u2018The long tail of Covid-19\u2019 \u2013The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res. 2020;9:1349. https:\/\/doi.org\/10.12688\/f1000research.27287.2.","journal-title":"F1000Res"},{"key":"2505_CR10","unstructured":"Centers for Disease Control. Management of post-COVID conditions. (2024). https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/post-covid-management.html. Accessed March 19, 2024."},{"key":"2505_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3026","volume":"370","author":"T Greenhalgh","year":"2020","unstructured":"Greenhalgh T, Knight M, A\u2019Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370: m3026. https:\/\/doi.org\/10.1136\/bmj.m3026.","journal-title":"BMJ"},{"issue":"7815","key":"2505_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290\u20135. https:\/\/doi.org\/10.1038\/s41586-020-2349-y.","journal-title":"Nature"},{"issue":"6620","key":"2505_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1126\/science.adc9127","volume":"378","author":"YJ Park","year":"2022","unstructured":"Park YJ, Pinto D, Walls AC, Liu Z, De Marco A, Benigni F, et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science. 2022;378(6620):619\u201327. https:\/\/doi.org\/10.1126\/science.adc9127.","journal-title":"Science"},{"issue":"(5)","key":"2505_CR14","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s15010-024-02245-6","volume":"52","author":"M Drysdale","year":"2024","unstructured":"Drysdale M, Berktas M, Gibbons DC, Rolland C, Lavoie L, Lloyd EJ. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review. Infection. 2024. https:\/\/doi.org\/10.1007\/s15010-024-02245-6.","journal-title":"Infection"},{"issue":"1","key":"2505_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s15010-023-02098-5","volume":"52","author":"M Drysdale","year":"2024","unstructured":"Drysdale M, Gibbons DC, Singh M, Rolland C, Lavoie L, Skingsley A, et al. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review. Infection. 2024;52(1):1\u201317. https:\/\/doi.org\/10.1007\/s15010-023-02098-5.","journal-title":"Infection"},{"key":"2505_CR16","unstructured":"N3C Dashboards. https:\/\/covid.cd2h.org\/dashboard\/. Accessed March 19, 2024."},{"issue":"7","key":"2505_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.16901","volume":"4","author":"TD Bennett","year":"2021","unstructured":"Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, et al. Clinical characterization and prediction of clinical severity of SARS-CoV-2 infection among US adults using data from the US National COVID Cohort Collaborative. JAMA Netw Open. 2021;4(7): e2116901. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.16901.","journal-title":"JAMA Netw Open"},{"issue":"25","key":"2505_CR18","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107. https:\/\/doi.org\/10.1002\/sim.3697.","journal-title":"Stat Med"},{"issue":"4","key":"2505_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067611","volume":"13","author":"J Tannous","year":"2023","unstructured":"Tannous J, Pan AP, Potter T, Bako AT, Dlouhy K, Drews A, et al. Real-world effectiveness of COVID-19 vaccines and anti-SARS-CoV-2 monoclonal antibodies against postacute sequelae of SARS-CoV-2: analysis of a COVID-19 observational registry for a diverse US metropolitan population. BMJ Open. 2023;13(4): e067611. https:\/\/doi.org\/10.1136\/bmjopen-2022-067611.","journal-title":"BMJ Open"},{"issue":"11","key":"2505_CR20","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/infdis\/jiab490","volume":"224","author":"MJ Peluso","year":"2021","unstructured":"Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;224(11):1839\u201348. https:\/\/doi.org\/10.1093\/infdis\/jiab490.","journal-title":"J Infect Dis"},{"key":"2505_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.08.21261763","author":"L Visvabharathy","year":"2022","unstructured":"Visvabharathy L, Hanson BA, Orban ZS, Lim PH, Palacio NM, Jimenez M, et al. T cell responses to SARS-CoV-2 in people with and without neurologic symptoms of long COVID. medRxiv. 2022. https:\/\/doi.org\/10.1101\/2021.08.08.21261763.","journal-title":"medRxiv"},{"issue":"7866","key":"2505_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03631-y","volume":"595","author":"EY Wang","year":"2021","unstructured":"Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283\u20138. https:\/\/doi.org\/10.1038\/s41586-021-03631-y.","journal-title":"Nature"},{"issue":"8","key":"2505_CR23","doi-asserted-by":"publisher","first-page":"e29014","DOI":"10.1002\/jmv.29014","volume":"95","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhao D, Xiao W, Shi J, Chen W, Jia Q, et al. Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge. J Med Virol. 2023;95(8): e29014. https:\/\/doi.org\/10.1002\/jmv.29014.","journal-title":"J Med Virol"},{"issue":"11","key":"2505_CR24","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.7326\/M23-1394","volume":"176","author":"GN Ioannou","year":"2023","unstructured":"Ioannou GN, Berry K, Rajeevan N, Li Y, Mutalik P, Yan L, et al. Effectiveness of nirmatrelvir-ritonavir against the development of post-COVID-19 conditions among U.S. veterans: a target trial emulation. Ann Intern Med. 2023;176(11):1486\u201397. https:\/\/doi.org\/10.7326\/M23-1394.","journal-title":"Ann Intern Med"},{"issue":"6","key":"2505_CR25","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","volume":"183","author":"Y Xie","year":"2023","unstructured":"Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023;183(6):554\u201364. https:\/\/doi.org\/10.1001\/jamainternmed.2023.0743.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"2505_CR26","doi-asserted-by":"publisher","first-page":"e29333","DOI":"10.1002\/jmv.29333","volume":"96","author":"MS Durstenfeld","year":"2024","unstructured":"Durstenfeld MS, Peluso MJ, Lin F, Peyser ND, Isasi C, Carton TW, et al. Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study. J Med Virol. 2024;96(1): e29333. https:\/\/doi.org\/10.1002\/jmv.29333.","journal-title":"J Med Virol"},{"issue":"22","key":"2505_CR27","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.2023.8823","volume":"329","author":"T Thaweethai","year":"2023","unstructured":"Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329(22):1934\u201346. https:\/\/doi.org\/10.1001\/jama.2023.8823.","journal-title":"JAMA"},{"issue":"9","key":"2505_CR28","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/infdis\/jiac136","volume":"226","author":"C Chen","year":"2022","unstructured":"Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226(9):1593\u2013607. https:\/\/doi.org\/10.1093\/infdis\/jiac136.","journal-title":"J Infect Dis"},{"key":"2505_CR29","doi-asserted-by":"publisher","first-page":"101762","DOI":"10.1016\/j.eclinm.2022.101762","volume":"55","author":"LL O'Mahoney","year":"2023","unstructured":"O\u2019Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023;55: 101762. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101762.","journal-title":"EClinicalMedicine"},{"key":"2505_CR30","doi-asserted-by":"publisher","DOI":"10.1101\/2022.08.15.22278603","author":"E Hill","year":"2022","unstructured":"Hill E, Mehta H, Sharma S, Mane K, Xie C, Cathey E, et al. Risk factors associated with post-acute sequelae of SARS-CoV-2 in an EHR cohort: a National COVID Cohort Collaborative (N3C) analysis as part of the NIH RECOVER program. medRxiv. 2022. https:\/\/doi.org\/10.1101\/2022.08.15.22278603.","journal-title":"medRxiv"},{"issue":"1","key":"2505_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12916-023-02737-6","volume":"21","author":"ER Pfaff","year":"2023","unstructured":"Pfaff ER, Madlock-Brown C, Baratta JM, Bhatia A, Davis H, Girvin A, et al. Coding long COVID: characterizing a new disease through an ICD-10 lens. BMC Med. 2023;21(1):58. https:\/\/doi.org\/10.1186\/s12916-023-02737-6.","journal-title":"BMC Med"},{"key":"2505_CR32","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1056\/NEJMc2216611","volume":"388","author":"J Walker","year":"2023","unstructured":"Walker J, Schnell G, Kerr W. Antiviral agents against Omicron subvariant BA.4.6 in vitro. N Engl J Med. 2023;388:e12. https:\/\/doi.org\/10.1056\/NEJMc2216611.","journal-title":"N Engl J Med"},{"key":"2505_CR33","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.09.434607","author":"AL Cathcart","year":"2022","unstructured":"Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid MA, Agostini ML, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. 2022. https:\/\/doi.org\/10.1101\/2021.03.09.434607.","journal-title":"bioRxiv"},{"key":"2505_CR34","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1038\/s41467-022-31615-7","volume":"13","author":"JB Case","year":"2022","unstructured":"Case JB, Mackin S, Errico JM, Chong Z, Madden EA, Whitener B, et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun. 2022;13:3824. https:\/\/doi.org\/10.1038\/s41467-022-31615-7.","journal-title":"Nat Commun"},{"key":"2505_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-022-04856-1","volume":"607","author":"R Uraki","year":"2022","unstructured":"Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature. 2022;607:119\u201327. https:\/\/doi.org\/10.1038\/s41586-022-04856-1.","journal-title":"Nature"},{"key":"2505_CR36","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.17.523798","author":"A Addetia","year":"2023","unstructured":"Addetia A, Piccoli L, Case JB, Park Y-J, Beltramello M, Guarino B, et al. Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants. bioRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.01.17.523798.","journal-title":"bioRxiv"},{"key":"2505_CR37","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40121-022-00755-0","volume":"12","author":"MM Cheng","year":"2023","unstructured":"Cheng MM, Reyes C, Satram S, Birch H, Gibbons DC, Drysdale M, et al. Real-world effectiveness of sotrovimab for the early treatment of COVID-19 during SARS-CoV-2 Delta and Omicron waves in the USA. Infect Dis Ther. 2023;12:607\u201321. https:\/\/doi.org\/10.1007\/s40121-022-00755-0.","journal-title":"Infect Dis Ther"},{"key":"2505_CR38","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/infdis\/jiac206","volume":"226","author":"NR Aggarwal","year":"2022","unstructured":"Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, et al. Real-world evidence of the neutralizing monoclonal antibody sotrovimab for preventing hospitalization and mortality in COVID-19 outpatients. J Infect Dis. 2022;226:2129\u201336. https:\/\/doi.org\/10.1093\/infdis\/jiac206.","journal-title":"J Infect Dis"},{"key":"2505_CR39","doi-asserted-by":"publisher","DOI":"10.1101\/2023.05.12.23289914","author":"J Tazare","year":"2023","unstructured":"Tazare J, Nab L, Zheng B, Hulme WJ, Green ACA, The Open Safely Collaborative, et al. Effectiveness of sotrovimab and molnupiravir in community settings in England across the Omicron BA.1 and BA.2 sublineages: emulated target trials using the OpenSAFELY platform. medRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.05.12.23289914.","journal-title":"medRxiv"},{"key":"2505_CR40","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1080\/03007995.2024.2376144","volume":"40","author":"V Patel","year":"2024","unstructured":"Patel V, Yarwood MJ, Levick B, Gibbons DC, Drysdale M, Kerr W, et al. Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England. Curr Med Res Opin. 2024;40:1323\u201334. https:\/\/doi.org\/10.1080\/03007995.2024.2376144.","journal-title":"Curr Med Res Opin"},{"key":"2505_CR41","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12879-024-09311-2","volume":"24","author":"V Patel","year":"2024","unstructured":"Patel V, Levick B, Boult S, Gibbons DC, Drysdale M, Lloyd EJ, et al. Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England. BMC Infect Dis. 2024;24:428. https:\/\/doi.org\/10.1186\/s12879-024-09311-2.","journal-title":"BMC Infect Dis"},{"key":"2505_CR42","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.20.23284849","author":"B Zheng","year":"2023","unstructured":"Zheng B, Tazare J, Nab L, Mehrkar M, MacKenna B, Goldacre B, et al. Comparative effectiveness of paxlovid versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients: observational cohort study using the OpenSAFELY platform. medRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.01.20.23284849.","journal-title":"medRxiv"},{"key":"2505_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071932","volume":"379","author":"B Zheng","year":"2022","unstructured":"Zheng B, Green ACA, Tazare J, et al. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform. BMJ. 2022;379: e071932. https:\/\/doi.org\/10.1136\/bmj-2022-071932.","journal-title":"BMJ"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02505-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02505-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02505-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:41:55Z","timestamp":1758721315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02505-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2505"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02505-z","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MD, JH, HB, CS, MVD, and IAG are employed by and hold financial equities in GSK. RC, TG, MSD, DL, SK, and MDS are employees of Analysis Group; Analysis Group received funding from GSK to conduct the study. Disclaimer: This article was prepared while SK was an employee of Analysis Group. The opinions expressed in this article are her own and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States government.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study complies with all applicable laws regarding subject privacy. No direct subject contact or primary collection of individual human subject data occurred. Study results were in tabular form and aggregate analyses that omit subject identification, therefore informed consent, ethics committee or Institutional Review Board (IRB) approval was not required. However, use of the N3C Limited Dataset requires IRB review. A request for a waiver of authorization was obtained from WCG IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All named authors meet the International Committee of Medical Journal Editors criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}